Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Colchicine Plus Phenolic Monoterpenes to Treat COVID-19

Mostafaie et al., ClinicalTrials.gov, NCT04392141, NCT04392141
Apr 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 83% primary Improvement Relative Risk Hospitalization time 35% Colchicine  Mostafaie et al.  LATE TREATMENT  RCT Is late treatment with colchicine + phenolic monoterpenes beneficial for COVID-19? RCT 120 patients in Iran (April - November 2020) Shorter hospitalization with colchicine + phenolic monoterpenes (p=0.0001) c19early.org Mostafaie et al., ClinicalTrials.gov, .., Apr 2021 Favorscolchicine Favorscontrol 0 0.5 1 1.5 2+
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
RCT with 60 patients treated with colchicine and phenolic monoterpenes and 60 control patients in Iran, showing lower mortality with treatment. NCT04392141 (history).
risk of death, 83.3% lower, RR 0.17, p = 0.11, treatment 1 of 60 (1.7%), control 6 of 60 (10.0%), NNT 12, primary outcome.
hospitalization time, 34.7% lower, relative time 0.65, p < 0.001, treatment 59, control 54.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mostafaie et al., 20 Apr 2021, Randomized Controlled Trial, Iran, preprint, 1 author, study period 1 April, 2020 - 1 November, 2020, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with phenolic monoterpenes) - results of individual treatments may vary, trial NCT04392141 (history).
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit